Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 1/20 | 0.47 |
| ▸ | HEXB | P07686 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297122 | 0.94 | HDAC3 (0.52) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3296718 | 0.93 | HDAC3 (0.50) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3297495 | 0.92 | HEXA (0.45) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3300198 | 0.88 | HEXA (0.53) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3296800 | 0.86 | HEXA (0.45) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3302527 | 0.86 | FTO (0.47) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL14528306 | 0.84 | HEXA (0.47) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL3300095 | 0.84 | FTO (0.49) | HEXAHEXBFTOCYP2D6POLB | |
| SCHEMBL3299639 | 0.84 | FTO (0.51) | HEXAHEXBFTOCYP2D6HDAC3 | |
| SCHEMBL13297981 | 0.82 | HEXA (0.48) | HEXAHEXBFTOCYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741337-B2 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | UNIBIOSCREEN S.A. (BE) | 2010-06-22 | — | — | US | claimed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | claimed |
| EP-1787985-A1 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | Unibioscreen S.A. (BE) | 2007-05-23 | — | — | EP | claimed |
| US-7741337-B2 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | UNIBIOSCREEN S.A. (BE) | 2010-06-22 | — | — | US | disclosed |
| US-7741337-B2 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | UNIBIOSCREEN S.A. (BE) | 2010-06-22 | — | — | US | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1787985-A1 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | Unibioscreen S.A. (BE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1787985-A1 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | Unibioscreen S.A. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HEXA 1944/4885HEXB 2802/4885FTO 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.